Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06736418 · ClinicalTrials.gov registry record · Phase 1
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
A Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma of the Lung, sponsored by Abdera Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 12
- Study locations
NCT06736418: Recruiting Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma of the Lung, sponsored by Abdera Therapeutics.
NCT06736418 is a Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma of the Lung that is actively recruiting participants, run by Abdera Therapeutics. The registered enrollment target is 65 participants, below the 289-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (78% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06736418, a Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma of the Lung, is actively recruiting participants, sponsored by Abdera Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 12
- Study locations
Study Summary
The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based chemotherapy. An initial group of patients will also be given an experimental imaging agent called 111In-ABD147 to help understand where ABD147 goes in the body. The goal of Phase 1b is to gather additional safety and efficacy data on 225Ac-ABD147 to determine the best dose and to understand how those doses affect the same types of patients' cancers explored enrolled in Phase 1a.
Primary Outcome
Incidence of adverse events and serious adverse events graded according to NCI-CTCAE v5.0; Clinically significant changes from baseline for laboratory values, ECGs, and vital signs will be evaluated as adverse events.
Conditions Studied
Interventions
- DRUG 225Ac-ABD147
Study Locations (12)
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
- University of California, San Francisco - San Francisco
- University of California, Los Angeles - Santa Monica
Florida
- Mayo Clinic - Jacksonville - Jacksonville
- Sylvester Comprehensive Cancer Center, Univ of Miami - Miami
- Florida Cancer Specialists - Sarasota - Sarasota
Maryland
- United Theranostics - Glen Burnie
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson - Houston
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What NCT06736418 shows while recruiting
NCT06736418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 289-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 1 intervention - of which 225Ac-ABD147 is the first listed.
NCT06736418 lists 12 locations in 8 states (California, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT06736418 about?
NCT06736418 is a clinical study titled "Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy". The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based c...
What is the current status of trial NCT06736418?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2025-03-10. Estimated completion is 2027-01.
What conditions does trial NCT06736418 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung.
What interventions are being tested in trial NCT06736418?
The interventions under investigation include: 225Ac-ABD147 (DRUG).
Who is sponsoring clinical trial NCT06736418?
This trial is sponsored by Abdera Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06736418 being conducted?
This trial has 12 study locations across California, Florida, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer (SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06736418's enrollment target sits among peer trials
65 10th of 12 higher than 2 of 12 other Small Cell Lung Cancer (SCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small Cell Lung Cancer (SCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI